Abstract
: There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / pharmacology*
-
Botswana
-
Drug Resistance, Multiple, Viral*
-
Genotype
-
HIV Infections / drug therapy
-
HIV Infections / virology*
-
HIV-1 / classification
-
HIV-1 / drug effects*
-
HIV-1 / genetics*
-
HIV-1 / isolation & purification
-
Heterocyclic Compounds, 3-Ring / administration & dosage
-
Heterocyclic Compounds, 3-Ring / pharmacology*
-
Humans
-
Male
-
Middle Aged
-
Mutation, Missense*
-
Oxazines
-
Piperazines
-
Pyridones
Substances
-
Anti-HIV Agents
-
Heterocyclic Compounds, 3-Ring
-
Oxazines
-
Piperazines
-
Pyridones
-
dolutegravir